Mednax Inc. (MD) Position Cut by Robeco Institutional Asset Management B.V.
Robeco Institutional Asset Management B.V. reduced its position in shares of Mednax Inc. (NYSE:MD) by 34.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 402,701 shares of the company’s stock after selling 212,414 shares during the period. Robeco Institutional Asset Management B.V. owned 0.43% of Mednax worth $26,679,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the stock. OLD Mutual Customised Solutions Proprietary Ltd. purchased a new position in Mednax during the second quarter valued at about $101,000. Parkside Financial Bank & Trust increased its position in Mednax by 30.1% in the second quarter. Parkside Financial Bank & Trust now owns 1,406 shares of the company’s stock valued at $102,000 after buying an additional 325 shares during the period. Mizuho Asset Management Co. Ltd. purchased a new position in Mednax during the second quarter valued at about $107,000. Pacer Advisors Inc. increased its position in Mednax by 9.5% in the second quarter. Pacer Advisors Inc. now owns 1,760 shares of the company’s stock valued at $127,000 after buying an additional 152 shares during the period. Finally, First Quadrant L P CA purchased a new position in Mednax during the second quarter valued at about $130,000. 98.45% of the stock is owned by institutional investors.
Shares of Mednax Inc. (NYSE:MD) traded up 0.72% during mid-day trading on Tuesday, hitting $65.80. The stock had a trading volume of 46,875 shares. The company has a 50-day moving average of $63.96 and a 200 day moving average of $67.35. Mednax Inc. has a one year low of $59.36 and a one year high of $76.96. The firm has a market cap of $6.09 billion, a price-to-earnings ratio of 18.07 and a beta of 0.62.
Mednax (NYSE:MD) last announced its earnings results on Thursday, October 27th. The company reported $1.09 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.11 by $0.02. Mednax had a net margin of 10.97% and a return on equity of 14.47%. The firm had revenue of $828 million for the quarter, compared to the consensus estimate of $821.18 million. During the same period in the prior year, the business earned $1.10 EPS. The company’s quarterly revenue was up 14.6% compared to the same quarter last year. On average, equities research analysts forecast that Mednax Inc. will post $4.04 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Mednax Inc. (MD) Position Cut by Robeco Institutional Asset Management B.V.” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2016/11/29/mednax-inc-md-position-cut-by-robeco-institutional-asset-management-b-v.html.
Several research firms have recently issued reports on MD. Citigroup Inc. cut their price target on Mednax from $76.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday, August 17th. Mizuho downgraded shares of Mednax from a “buy” rating to a “neutral” rating and cut their target price for the company from $69.00 to $64.00 in a research note on Wednesday, November 9th. Zacks Investment Research downgraded shares of Mednax from a “hold” rating to a “sell” rating in a research note on Wednesday, September 28th. Raymond James Financial Inc. downgraded shares of Mednax from an “outperform” rating to a “market perform” rating in a research note on Thursday, October 27th. Finally, Jefferies Group cut their target price on shares of Mednax from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Friday, August 26th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $74.44.
In other news, Director Md Pascal J. Goldschmidt sold 1,500 shares of the company’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $65.01, for a total transaction of $97,515.00. Following the completion of the sale, the director now directly owns 12,755 shares of the company’s stock, valued at $829,202.55. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 2.40% of the company’s stock.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Stock Ratings for Mednax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc. and related stocks with our FREE daily email newsletter.